NVO — NOVO NORDISK A S

—
NYSE · Health Care · Pharmaceuticals · CIK 353278 ·
Last close
$40.70
Market Cap
$136.10B
52W High
$61.11
52W Low
$34.15
ADV30
11,672,867
Next earnings
—

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 79,195,000,000 60,958,000,000 23,011,000,000 16,740,000,000 599,160,000,000 44,151,000,000 381,358,000,000
Jun 2026 78,488,000,000 61,388,000,000 27,061,000,000 20,989,000,000 594,941,000,000 44,482,000,000 373,664,000,000
Mar 2026 96,823,000,000 83,225,000,000 59,618,000,000 48,557,000,000 559,221,000,000 21,127,000,000 356,156,000,000
Dec 2025 79,144,000,000 63,996,000,000 31,736,000,000 26,891,000,000 542,902,000,000 26,464,000,000 348,855,000,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$127,325,000,000
Investing CF
$-83,350,000,000
Financing CF
$-31,871,000,000
CapEx
$-82,356,000,000
Dividends Paid
$-51,896,000,000
Buybacks
$-10,002,000,000
EPS Diluted TTM
$25.48
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$220,552,000,000
Inventory
$51,205,000,000
Receivables
$110,606,000,000
ST Investments
$2,201,000,000
EBIT TTM
$148,793,000,000
Pretax Income TTM
$144,666,000,000
Interest Exp TTM
$2,170,000,000
Analysts
12

Yahoo Snapshot (yfinance, live)

Total Revenue
$329,430,990,848
EBITDA
$173,677,002,752
Free Cash Flow
$37,673,250,816
Enterprise Value
$285,861,511,168
Total Cash
$44,982,001,664
Total Debt
$140,126,994,432
Shares Out
3,344,053,124
Trailing EPS
$4.09
Book Value
$7.74
ROE
59.8%
ROA
18.7%
Div Yield
4.17%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 309,064,000,000 127,658,000,000 102,434,000,000 542,902,000,000 348,855,000,000 194,047,000,000 119,102,000,000
Dec 2024 290,403,000,000 128,339,000,000 100,988,000,000 465,630,000,000 322,144,000,000 143,486,000,000 120,968,000,000
Dec 2023 232,261,000,000 102,574,000,000 83,683,000,000 314,486,000,000 207,925,000,000 106,561,000,000 108,908,000,000
Dec 2022 176,954,000,000 74,809,000,000 55,525,000,000 241,257,000,000 157,771,000,000 83,486,000,000 78,887,000,000

TTM Snapshot

Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$3.40

Peers — same industry

TickerNameMarket CapLastDaily %
VRTX VERTEX PHARMACEUTICALS INC / MA $135.44B $534.20 —
BMY BRISTOL MYERS SQUIBB CO $125.40B $61.35 —
PFE PFIZER INC $162.27B $28.47 —
SNY Sanofi $113.89B $47.53 —
ABT ABBOTT LABORATORIES $181.35B $104.71 —

News headlines (Yahoo Finance, 1h cache)

nference and Novo partner to advance understanding of cardiometabolic disease and healthy ageing
2026-11-18 10:30 · Yahoo
Novo Nordisk (NVO) Stock May Be Undervalued On Raised 2026 Outlook
2026-11-18 06:17 · Yahoo
Novo Nordisk (NVO) Could Be 47% Below Fair Value Following Its AI Push
2026-11-18 05:12 · Yahoo
Eli Lilly vs. Novo Nordisk: Which GLP-1 Stock Is a Better Buy for 2027?
2026-11-17 21:37 · Yahoo
European Equities Traded in the US as American Depositary Receipts Tumble in Tuesday Trading
2026-11-17 16:20 · Yahoo
Novo launches the new Novocare®: Free support program connects people with Wegovy® in addition to home delivery, everyday support, wellness partners and rewards
2026-11-17 13:00 · Yahoo
Johnson & Johnson vs. Novo Nordisk: Steady Uptrend vs. Flat Revenue
2026-11-17 11:45 · Yahoo
Novo presents preclinical and human data suggesting a role for amylin and calcitonin receptor activation in preserving bone during weight loss at ObesityWeek®
2026-11-16 22:00 · Yahoo
European Stocks Close Mostly Lower in Monday Trading; Investors Parse Earnings, Look Ahead to Trilateral Summit
2026-11-16 16:56 · Yahoo
Novo Nordisk vs. Amgen: 1 Has the Blockbuster Weight-Loss Drugs, the Other Has a Promising Rival
2026-11-16 16:06 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.